Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Foundayo Eli Lilly weight loss pill: Eli Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral m...

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...

Wegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...

Reuters spoke to three-dozen people inside the industry including retailers, drugmakers, telehealth providers and investors to show how the...

Novo Nordisk's popular weight-loss drug Wegovy is now available as a pill in the US. The US Food and Drug Administration has approved the o...

GLP-1 medications are prescription treatments used in the UK to manage type 2 diabetes and, in certain cases, medically supervised weight l...

Sales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...

Eli Lilly's experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients across two lat...

Lilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatid...

Eli Lilly's new pill shows promise. The drug helped people with diabetes lose weight in trials. The pill, orforglipron, led to a 10.5% weig...

Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of...

Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...

Pfizer has halted the development of its experimental weight-loss pill, danuglipron, following a trial participant's liver injury, which re...

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.